Treatment of Advanced Fumarate Hydratase (FH)-Deficient Renal Cell Carcinoma

Clinical Scenario

This protocol applies to patients with advanced renal cell carcinoma harbouring fumarate hydratase (FH) deficiency — a molecularly defined subtype, also associated with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), that is managed distinctly from conventional advanced RCC.

Treatment Approach

The approach involves a combination regimen supported by phase II data in FH-deficient disease. Full regimen details, sequencing, and dosing instructions are available in the structured protocol.

Complete regimen available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

Bevacizumabeerlotinib may be used in advanced FH-deficient RCC.
Data from a phase II study investigating bevacizumabeerlotinib in HLRCC-associated RCC support the use of this combination in advanced FH-deficient disease.

DOI: 10.1016/j.annonc.2024.05.537

View source ↗